Naser Ahmad Joudeh - 03 Mar 2021 Form 4 Insider Report for Medicine Man Technologies, Inc. (SHWZ)

Reporting relationship: Filer
Issuer ticker: SHWZ
Reported as of: 03 Mar 2021
Net transaction value: +$1,959,000
SEC form: 4
Accepted by SEC: 12 Jul 2021, 14:57:36 UTC
Prior SEC filing: 12 Jul 2021
Source filing: View source filing
Reporting owner signature: Naser Ahmad Joudeh

Key filing fact

Naser Ahmad Joudeh filed Form 4 for Medicine Man Technologies, Inc. (SHWZ) on 12 Jul 2021.

Key facts

This page summarizes Naser Ahmad Joudeh's Form 4 filing for Medicine Man Technologies, Inc. (SHWZ).
6 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 12 Jul 2021, 14:57.

Change

Previous filing in this sequence was filed on 12 Jul 2021.
Current net transaction value: +$1,959,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SHWZ transaction Derivative

Series A Cumulative Convertible Preferred Stock

Award

Transaction value: $547,000
Shares: +547
Change %: +22%
Price: $1000.00^*
Shares after: 2,990
Date: 02 Mar 2021
Ownership: Direct
Underlying class: Common stock
Underlying amount: 455,833
Exercise price: $1.20
Footnotes: F1, F2, F3

SHWZ transaction Derivative

Series A Cumulative Convertible Preferred Stock

Award

Transaction value: $865,000
Shares: +865
Change %: +29%
Price: $1000.00^*
Shares after: 3,855
Date: 02 Mar 2021
Ownership: Spouse
Underlying class: Common stock
Underlying amount: 720,833
Exercise price: $1.20
Footnotes: F1, F2, F3

SHWZ transaction Derivative

Series A Cumulative Convertible Preferred Stock

Award

Transaction value: $547,000
Shares: +547
Change %: +7.7%
Price: $1000.00^*
Shares after: 7,683
Date: 02 Mar 2021
Ownership: Spouse
Underlying class: Common stock
Underlying amount: 3,190,000
Exercise price: $1.20
Footnotes: F1, F2, F3

SHWZ transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +102,548
Change %
Price
Shares after: 102,548
Date: 02 Mar 2021
Ownership: Direct
Underlying class: Common stock
Underlying amount: 102,548
Exercise price: $1.20
Footnotes: F4

SHWZ transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +162,044
Change %: +158%
Price
Shares after: 264,592
Date: 02 Mar 2021
Ownership: Spouse
Underlying class: Common stock
Underlying amount: 162,044
Exercise price: $1.20
Footnotes: F4

SHWZ transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +717,870
Change %: +271%
Price
Shares after: 982,462
Date: 02 Mar 2021
Ownership: Spouse
Underlying class: Common stock
Underlying amount: 717,870
Exercise price: $1.20
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Subject to adjustment, as described in the Certificate of Designation.

Footnote F2

The shares of Series A Cumulative Convertible Preferred Stock (the "Series A Preferred Shares") are convertible into shares of the common stock (the "Common Shares") of Medicine Man Technologies, Inc. (the "Company") upon the events specified in the Company's Certificate of Designation of Series A Cumulative Convertible Preferred Stock (the "Certificate of Designation"). The Preferred stock is perpetual and therefore has no expiration date.

Footnote F3

Represents the number of Common Shares issuable upon conversion of the Series A Preferred Shares on the date of the reported transaction. Each Series A Preferred Share is convertible into that number of Common Shares equal to the preference amount (initially $1,000) plus any accrued dividends with respect to such share, divided by the conversion price (initially $1.20), subject to adjustment as set forth in the Certificate of Designation. The Series A Preferred Shares earn a cumulative dividend of 8% per annum.

Footnote F4

The reporting person received the warrants under Asset Purchase Agreements entered into by entities partly-owned by the reporting person upon the sale of assets by such entities to the issuer on the following date: March 3, 2021.